A novel colistin adjuvant identified by virtual screening for ArnT inhibitors
- PMID: 32514531
- PMCID: PMC7443731
- DOI: 10.1093/jac/dkaa200
A novel colistin adjuvant identified by virtual screening for ArnT inhibitors
Abstract
Background: Colistin is a last-resort treatment option for many MDR Gram-negative bacteria. The covalent addition of l-aminoarabinose to the lipid A moiety of LPS is the main colistin resistance mechanism in the human pathogen Pseudomonas aeruginosa.
Objectives: Identification (by in silico screening of a chemical library) of potential inhibitors of ArnT, which catalyses the last committed step of lipid A aminoarabinosylation, and their validation in vitro as colistin adjuvants.
Methods: The available ArnT crystal structure was used for a docking-based virtual screening of an in-house library of natural products. The resulting putative ArnT inhibitors were tested in growth inhibition assays using a reference colistin-resistant P. aeruginosa strain. The most promising compound was further characterized for its range of activity, specificity and cytotoxicity. Additionally, the effect of the compound on lipid A aminoarabinosylation was verified by MS analyses of lipid A.
Results: A putative ArnT inhibitor (BBN149) was discovered by molecular docking and demonstrated to specifically potentiate colistin activity in colistin-resistant P. aeruginosa isolates, without relevant effect on colistin-susceptible strains. BBN149 also showed adjuvant activity against colistin-resistant Klebsiella pneumoniae and low toxicity to bronchial epithelial cells. Lipid A aminoarabinosylation was reduced in BBN149-treated cells, although only partially.
Conclusions: This study demonstrates that in silico screening targeting ArnT can successfully identify inhibitors of colistin resistance and provides a promising lead compound for the development of colistin adjuvants for the treatment of MDR bacterial infections.
© The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
Figures





References
-
- Storm DR, Rosenthal KS, Swanson PE.. Polymyxin and related peptide antibiotics. Annu Rev Biochem 1977; 46: 723–63. - PubMed
-
- Jeannot K, Bolard A, Plésiat P.. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 2017; 49: 526–35. - PubMed
-
- Falagas ME, Rafailidis PI, Matthaiou DK.. Resistance to polymyxins: mechanisms, frequency and treatment options. Drug Resist Updat 2010; 13: 132–8. - PubMed
-
- Pedersen MG, Olesen HV, Jensen-Fangel S. et al. Colistin resistance in Pseudomonas aeruginosa and Achromobacter spp. cultured from Danish cystic fibrosis patients is not related to plasmid-mediated expression of mcr-1. J Cyst Fibros 2018; 17: e22–3. - PubMed
-
- Schülin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 2002; 49: 403–6. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources